A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Women who are pregnant or lactating or are planning on becoming pregnant during the study.

A current diagnosis of asthma

Known alpha-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer

Other significant respiratory conditions in addition to COPD

Other diseases that are uncontrolled including cancer in remission for less than 5 years

Chest x-ray or CT scan with clinically significant abnormalities not believed to be due to the presence of COPD

Hypersensitivity to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate

A medical condition that contraindicates study participation or use of an inhaled anticholinergic

Hospitalization for COPD or pneumonia within 12 weeks of Visit 1

Any previous lung resection surgery

A body mass index (BMI) value of \>35 kilogram (kg)/meter squared (m2)

An abnormal and significant electrocardiogram finding at Visit 1

Significantly abnormal finding from clinical chemistry or haematology tests at Visit 1.

A positive Hepatitis B surface antigen or positive Hepatitis C antibody

Medically unable to withhold albuterol (salbutamol) for the 6 hour period prior to study visits

Use of depot corticosteroids within 12 weeks of Visit 1

Use of oral or parenteral corticosteroids or antibiotics for lower respiratory tract infection within 6 weeks of Visit 1

Use of long-acting beta-agonist (LABA)/inhaled corticosteroid (ICS) product if LABA/ICS therapy is discontinued within 30 days of Visit 1

Use of ICS at a dose of \>1000mcg/day of fluticasone propionate or equivalent within 30 days of Visit 1

Initiation or discontinuation of ICS within 30 days of Visit 1

Use of tiotropium or phosphodiesterase 4 inhibitors within 14 days of Visit 1

Use of theophyllines, oral leukotriene inhibitors, long-acting oral beta-agonists, or inhaled long-acting beta-agonists within 48 hours of Visit 1

Short-acting oral beta-agonists within 12 hours of Visit 1

Use of LABA/ICS combination products only if discontinuing LABA therapy and switching to ICS monotherapy within 48 hours of Visit 1 for the LABA component

Use of sodium cromoglycate or nedocromil sodium within 24 hours of Visit 1

Use of inhaled short-acting beta-agonists, inhaled short-acting anticholinergics, or inhaled short-acting anticholinergic/short-acting beta-agonist combination products within 6 hours of Visit 1

Use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer)

Oxygen therapy prescribed for greater than 12 hours a day

Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators

Use of continuous positive airway pressure (CPAP), nocturnal positive pressure or non-invasive positive pressure ventilation (NIPPV), including use for sleep apnea.

Acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1

A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1

Anyone affiliated with investigator site

Previous use of GSK573719 or GSK53719/GW642444

What this study is about